Related Experiment Video
Updated: Sep 22, 2025

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions
Published on: October 21, 2022
CircRNA-miRNA interactions in atherogenesis
Kind-Leng Tong1, Ke-En Tan2, Yat-Yuen Lim2
1Department of Pharmacology, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
Insights
Circular RNAs (circRNAs) play a critical role in atherogenesis, the development of atherosclerosis. This review details circRNA-miRNA-mRNA interactions driving cardiovascular disease progression.
Area of Science:
- Molecular Biology
- Cardiovascular Research
- Epigenetics
Background:
- Atherosclerosis, a primary cause of coronary artery disease (CAD), involves lipid accumulation, oxidative stress, and inflammation.
- Endothelial cell (EC) dysfunction, vascular smooth muscle cell (VSMC) activation, and foam cell formation are key pathogenic events.
- Circular RNAs (circRNAs) are increasingly recognized for their roles in cardiovascular diseases.
Purpose of the Study:
- To review current knowledge on circRNAs involved in atherogenesis.
- To analyze the complex circRNA-microRNA (miRNA)-messenger RNA (mRNA) interactions in the context of atherosclerosis.
- To identify knowledge gaps and discuss the clinical relevance of these circRNAs.
Main Methods:
- Systematic literature review of studies on circRNAs in atherogenesis.
- Analysis of reported circRNA-miRNA-mRNA regulatory networks.
- Discussion of the mechanistic roles and clinical implications of identified circRNAs.
Main Results:
- circRNAs function primarily by sponging miRNAs, thereby modulating mRNA expression.
- Specific circRNA-miRNA-mRNA axes have been linked to key atherogenic processes.
- Evidence highlights the involvement of circRNAs in EC dysfunction, VSMC activation, and foam cell formation.
Conclusions:
- circRNAs are significant regulators of atherogenesis through intricate molecular interactions.
- Understanding these circRNA networks offers potential therapeutic targets for CAD.
- Further research is needed to fully elucidate the clinical utility of circRNAs in cardiovascular medicine.
Abstract:
Atherosclerosis is the major cause of coronary artery disease (CAD) which includes unstable angina, myocardial infarction, and heart failure. The onset of atherogenesis, a process of atherosclerotic lesion formation in the intima of arteries, is driven by lipid accumulation, a vicious cycle of reactive oxygen species (ROS)-induced oxidative stress and inflammatory reactions leading to endothelial cell (EC) dysfunction, vascular smooth muscle cell (VSMC) activation, and foam cell formation which further fuel plaque formation and destabilization. In recent years, there is a surge in the number of publications reporting the involvement of circular RNAs (circRNAs) in the pathogenesis of cardiovascular diseases, cancers, and metabolic syndromes. These studies have advanced our understanding on the biological functions of circRNAs. One of the most common mechanism of action of circRNAs reported is the sponging of microRNAs (miRNAs) by binding to the miRNAs response element (MRE), thereby indirectly increases the transcription of their target messenger RNAs (mRNAs). Individual networks of circRNA-miRNA-mRNA associated with atherogenesis have been extensively reported, however, there is a need to connect these findings for a complete overview. This review aims to provide an update on atherogenesis-related circRNAs and analyze the circRNA-miRNA-mRNA interactions in atherogenesis. The atherogenic mechanisms and clinical relevance of each atherogenesis-related circRNA were systematically discussed for better understanding of the knowledge gap in this area.
More Related Videos
Related Concept Videos
MicroRNAs
Atherosclerosis I: Introduction
Coronary Artery Disease II: Pathophysiology
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Atherosclerosis III: Management
Experimental RNAi

